Here’s why you should invest in HDFC Charity Fund for Cancer Cure

By: |
Published: March 15, 2017 3:47:41 PM

HDFC Charity Fund for Cancer Cure is a close-ended equity-oriented scheme which enables the unit holders to donate full or part of dividend declared by the fund to the corpus of the Indian Cancer Society or any other eligible institution(s) for the treatment of cancer.

This scheme will help investors generate regular income over its tenure (1136 days). However, investors understand that their principal will be at moderately low risk while investing in the following equity scheme.

HDFC Charity Fund for Cancer Cure is a close-ended equity-oriented scheme which enables the unit holders to donate full or part of dividend declared by the fund to the corpus of the Indian Cancer Society or any other eligible institution(s) for the treatment of cancer. Such donations made by the Mutual Fund/ AMC on behalf of the unit holders shall be eligible for claiming deduction under Section 80G of Income Tax Act,1961.

This scheme will help investors generate regular income over its tenure (1136 days). However, investors understand that their principal will be at moderately low risk while investing in the following equity scheme.

New Fund Offer time period
New Fund Offer opens on March 10, 2017, and closes on March 24, 2017.

You may also watch:

Investment Objective
Arbitrage Plan: To generate income through arbitrage opportunities between cash and derivative market and through investments in debt and money market instruments.
Debt Plan: To generate income through investments in Debt / Money Market Instruments and Government Securities maturing on or before the maturity date of the Plan. However, there can be no assurance that the investment objective of the Scheme/ Plan(s) will be realized.

Asset Allocation


*Investment in a securitized debt shall not normally exceed 35% of the net assets of the Scheme.

When adequate arbitrage opportunities are not available in the derivative and equity markets, the asset allocation of the Arbitrage Plan’s portfolio will be as follows:

*Investment in a securitized debt shall not normally exceed 50% of the net assets of the scheme.


*The Debt Plan shall not have an exposure of more than 35% of its assets in foreign debt securities in accordance with guidelines stipulated in this regard by SEBI and RBI from time to time. Investment in securitized debt, if undertaken, would not exceed 75% of the net assets of the scheme. The total gross exposure through investment in debt + money market instruments + derivatives (fixed income) shall not exceed 100% of net assets of the Scheme. Security-wise hedge positions using derivatives such as Interest Rate Swaps, Futures, etc. will not be considered in calculating above exposure.

Minimum Application Amount
Purchase: Rs.50,000/- and in multiples Rs.1,000/- thereafter
Additional Purchase: Not Applicable
Repurchase: Not Applicable. The units will be listed on the stock exchange(s). The scheme will not provide redemption facility until the date of maturity/ final redemption date.

Benchmark Index
Arbitrage Plan – NIFTY 50 Arbitrage Index
Debt Plan – CRISIL Short Term Bond Fund Index

You may also watch:

Disclaimer of NSE / BSE
It is to be distinctly understood that the permission given by National Stock Exchange of India Limited (NSE) / BSE Limited (BSE) should not in any way be deemed or construed that the Scheme Information Document (SID) has been cleared or approved by NSE/ BSE nor does it certify the correctness or completeness of any of the contents of the Draft SID. The investors are advised to refer to the SID for the full text of the disclaimer clauses of NSE/BSE.

It is to be noted that investors should consult their financial advisers if in doubt about whether the product is suitable for them or not.

(Source Input: hdfcfund.com)

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.